Complications of Continuous Mupirocin Use
Prolonged use of mupirocin carries two primary risks: development of bacterial resistance (particularly high-level mupirocin-resistant Staphylococcus aureus) and overgrowth of nonsusceptible organisms including fungi 1.
Primary Concerns with Long-Term Use
Antibiotic Resistance Development
The most clinically significant complication is the emergence of mupirocin-resistant organisms. Research demonstrates that continuous treatment can lead to resistance in S. aureus strains 2. In patients with epidermolysis bullosa treated long-term (some for over 4 years), mupirocin-resistant S. aureus emerged in nonhealing wounds, requiring switch to oral antibiotics 2.
Resistance patterns include:
- High-level mupirocin resistance (HLMuR): MIC ≥512 µg/mL
- Low-level mupirocin resistance (LLMuR): MIC 8-256 µg/mL
- Recent surveillance data shows resistance rates of 3.2% overall, though this varies by institution and time period 3
Fungal and Nonsusceptible Organism Overgrowth
The FDA label explicitly warns that prolonged use results in overgrowth of nonsusceptible organisms, including fungi 1. This occurs because mupirocin's narrow spectrum (primarily gram-positive cocci) creates an ecological niche for resistant bacteria and fungi to proliferate.
Additional Complications
Polyethylene Glycol Toxicity
Mupirocin ointment contains polyethylene glycol base, which can be absorbed through open wounds and damaged skin, then excreted by kidneys 1. This is particularly dangerous in patients with moderate-to-severe renal impairment, where accumulation can occur. The FDA specifically contraindicates use in conditions allowing large-scale polyethylene glycol absorption when renal function is compromised 1.
Local Adverse Reactions
While generally well-tolerated, continuous use increases cumulative exposure risk for:
- Burning, stinging, or pain (1.5% incidence)
- Itching (1% incidence)
- Contact dermatitis, rash, erythema, dry skin (each <1%) 1
- Chemical irritation requiring discontinuation 1
Clinical Pitfalls to Avoid
Do not use mupirocin continuously beyond 5-day courses without specific indication. Guidelines recommend intermittent decolonization regimens (5 days monthly) rather than continuous application 4. Even these intermittent regimens show questionable efficacy in the current MRSA era—one randomized trial in military personnel found twice-daily nasal mupirocin for 5 days did not reduce subsequent skin infections 4.
Monitor for treatment failure after 3-5 days 1. If impetigo or other infection hasn't improved within this timeframe, consider resistance development and culture the wound.
Avoid in patients with renal impairment when treating large surface areas or open wounds due to polyethylene glycol absorption risk 1.
When Continuous Use Might Be Considered
The only scenario where extended mupirocin use has evidence is recurrent MRSA infections, where monthly 5-day courses (not continuous daily use) combined with chlorhexidine bathing may be attempted 4. However, even this approach has sparse efficacy data and should not be first-line given resistance concerns.
The key principle: mupirocin should be used in short, defined courses (typically 5 days), not as continuous prophylaxis or maintenance therapy 1, 5.